Skip to content

Sera Prognostics SERA Return on equity

Return on equity at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
-76.7%-98.4pp
Labcorp Holdings logo
Labcorp HoldingsLH
11.1%+2.1pp
Quest Diagnostics logo
Quest DiagnosticsDGX
14.3%+0.9pp
Natera, Inc. logo
Natera, Inc.NTRA
-29%+4.1pp
Revvity logo
RevvityRVTY
3.2%-0.5pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-41.4%-6.7pp

Other financials

Income statement

See full
Revenue$14.0K-63.2%
Operating income-$9.4M-1.2%
Net income-$8.4M-2.6%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$4.2M-20.2%
Total debt$2.5M+286%
Total equity$67.6M-28.7%
Total assets$93.5M-20.8%

Cash flow

See full
Operating cash flow-$8.8M-16.2%
CapEx$8.0K+167%
Free cash flow-$8.8M-16.2%

Valuation

See full
Market cap$71.27M-4.5%
Enterprise value$69.6M-0.5%
P/S1,250.3×+560×

Profitability

See full
Operating margin-64,235.1%-8,092,342pp
Net margin-56,386%+1,586,573pp
FCF margin-48,377.2%-673,104pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio2.1×+0.1×

Where this comes from

Calculated from Sera Prognostics’s reported figures.

Based on trailing twelve months.

The official record: Sera Prognostics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sera Prognostics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sera Prognostics's return on equity?
Sera Prognostics (SERA) reported return on equity of -39.6% in Q1 2026.
How has Sera Prognostics's return on equity changed year-over-year?
Sera Prognostics's return on equity increased by 4.3% year-over-year, from -41.4% to -39.6%.
What is the long-term trend for Sera Prognostics's return on equity?
Over 3 years (2022 to 2025), Sera Prognostics's return on equity has grown at a 11.7% compound annual growth rate (CAGR), from -37.2% to -51.8%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.